, Volume 10, Issue 3, pp 185–239 | Cite as

Recent pharmacodynamic and pharmacokinetic findings on oxaprozin

  • K. D. Rainsford
  • H. Omar
  • A. Ashraf
  • A. T. Hewson
  • R. A. D. Bunning
  • R. Rishiraj
  • P. Shepherd
  • R. W. Seabrook


Oxaprozin has proven a safe and effective treatment for arthritic conditions. It has a low incidence of gastrointestinal side effects making it a particularly attractive therapy. Being an unselective COX-1 and COX-2 inhibitor the drug may have advantages in more effective pain relief related to both COX-1 as well as COX-2 effects. We have investigated the pharmacology of oxaprozin on (a) the biochemical components of joint destruction in vitro, and (b) the pharmacokinetic interactions of this drug with albumin in vitro in which drug interactions are modelled by competitive binding of the drug with endogenous ligands or drugs that are commonly prescribed with NSAIDs. The latter in vitro pharmacokinetic study can be considered as a basis for understanding both safety and therapeutic activity of the drug. Among the major effects of oxaprozin (10-100 μM) observed on components of joint destruction was (a) the inhibition of the production of interleukin-1β (IL-1β) from pig synovial tissues in organ culture and IL-1β, IL-6 and IL-8, as well as tumour necrosis factor-α (TNFα) from THP-1 mononuclear cells at 50-100 μM. Oxaprozin (1.0-100 μM) did not affect NO production from porcine synovial tissue, whereas indomethacin and nimesulide reduced production of NO. Oxaprozin did not exacerbate the IL-1β and/or TNFα-induced proteoglycan destruction in pig or bovine cartilage in organ culture as observed with indomethacin and aspirin. Radiolabelled oxaprozin accumulated in cartilage to a much greater extent than observed with other NSAIDs. This may be a particular advantage in enabling expression of cartilage protective effects of the drug. Albumin binding of [14C]oxaprozin (10 μM) in vitro was unaffected by other NSAIDs (e.g., aspirin, diclofenac, ibuprofen, paracetamol, salicylate), a range of commonly co-prescribed drugs (e.g., atenolol, clonidine, cromolyn, diphenhydramine, furosemide, ketotifen, salbutamol, prednisolone, theophylline), endogenous steroids (e.g., oestradiol, progesterone) or other agents (e.g., caffeine) at concentrations of 40 μM. The free concentrations of oxaprozin were, however, increased slightly by the same concentrations of warfarin, prednisolone, diazepam and captopril. In contrast, the binding of oxaprozin to free-fatty acid depleted albumin was only appreciably affected by captopril and caffeine. The free oxaprozin was slightly increased by zinc and copper ions (which are increased in rheumatic conditions) in normal as well as fatty acid-free albumin. Tryptophan release from albumin, which has a role in central analgesic actions of anti-rheumatic drugs by enhancing CNS turnover of 5-hydroxytryptamine (serotonin), was increased by 50-100 μM oxaprozin, as well as other NSAIDs. This indicates that serotonergic activation could also contributed to the analgesic properties of oxaprozin like that of other NSAIDs. These studies indicate that the potentially-significant pharmacodynamic actions of oxaprozin in arthritic joints may involve inhibition of the release of pro-inflammatory cytokines from inflamed synovium and relatively high rate of drug uptake into inflamed joints. Analgesia, in addition to being a consequence of prostaglandin inhibition, may be initiated by release of albumin-bound tryptophan and uptake into the brains leading to activate serotonergic pathways of pain suppression. Oxaprozin is only slightly affected pharmacokinetically by some co-prescribed drugs or patho-physiologic metal ions but these effects may be of limited clinical consequence principally as oxaprozin has a relatively long plasma elimination half-life (50-60 h) and any small increase in free concentrations of the drug in circulating plasma increases elimination of the drug.

NSAIDs propionic acids arthritis serotonin albumin cytokines. 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Audet, P. R., Knowles, J. A., Troy, S. M., et al. (1988). Effect of chronic renal failure on oxaprozin multiple-dose pharmacokinetics, Clin. Pharmacol. Ther. 44, 303–309.PubMedGoogle Scholar
  2. Ashcroft, G. W., Crawford, T. B., Cundall, R. L., et al. (1973). 5-Hydroxytryptamine metabolism in affective illness: the effect of tryptophan administration, Psychol. Med. 3, 326–332.PubMedGoogle Scholar
  3. Aubry, A. F., Markoglou, N., Adams, M. H., et al. (1995). The effect of co-administered drugs on oxaprozin binding to human serum albumin, J. Pharm. Pharmacol. 47, 937–944.PubMedGoogle Scholar
  4. Aylward, M. and Maddock, J. (1973). Total and free-plasma tryptophan concentrations in rheumatoid disease, J. Pharm. Pharmacol. 25, 570–572.PubMedGoogle Scholar
  5. Badawy, A. A.-B. (1982). Mechanisms of elevation of rat brain tryptophan concentration by various doses of salicylate, Br. J. Pharmacol. 76, 211–213.PubMedGoogle Scholar
  6. Barracchini, A., Franceschini, N., Amicosante, G., et al. (1998). Can non-steroidal anti-inflammatory drugs act as metalloproteinase modulators? An in vitro study of inhibition of collagenase activity, J. Pharm. Pharmacol. 50, 1417–1423.PubMedGoogle Scholar
  7. Barracchini, A., Minisola, G., Amicosante, G., et al. (2001). Oxaprozin: An NSAID able to inhibit the matrix metallo-proteinase activity, Inflammopharmacology 9, 143–146.Google Scholar
  8. Barbato, F., Caliendo, G., La Rotonda, M. I., et al. (1986). Distribution coefficients by curve fitting: application to ionogenic nonsteroidal anti-inflammatory drugs, Quant. Struct.-Activity Relat. 5, 88–95.Google Scholar
  9. Bender, D. A and McCreanor, G. M. (1982). The preferred route of kynurenine metabolismin the rat, Biochim. Biophys. Acta 717, 56–60.PubMedGoogle Scholar
  10. Bickel, M. H. and Gerny, R. (1980). Drug distribution as a function of binding competition. Experiments with the distributiondialysis technique, J. Pharm. Pharmacol. 32, 669–674.Google Scholar
  11. Bonney, S. L., Hedrich, D. A. and Walker, B. R. (1987). Oxaprozin, in: Nonsteriodal Anti-infl ammatory Drugs. Mechanisms and Clinical Use, Lewis, A. J. and Furst, D. E. (Eds), pp. 473–486. Marcel Dekker, New York.Google Scholar
  12. Bonney, S. L., Northington, R. S., Hedrich, D. A., et al. (1986). Renal safety of two analgesics used over the counter: ibuprofen and aspirin, Clin. Pharmacol. Ther. 40, 373–377.PubMedGoogle Scholar
  13. Chiang, S. T., Morrison, G., Knowles, J. A., et al. (1982). Oxaprozin dispositionin renal disease, Clin. Pharmacol. Ther. 31, 509–515.PubMedGoogle Scholar
  14. Couchman, K. G. and Sheppeard, H. (1986). The effect of anti-rheumatic drugs on factors from porcine synovium inducing chondrocyte mediated cartilage degradation, Agents Actions 19, 116–122.PubMedGoogle Scholar
  15. Crofford, L.J. (1997). COX-1 and-2 tissue expression; implications and prediction, J. Rheumatol. 24, 15–19.Google Scholar
  16. Crofford, L. J., Wilder, R. L., Risimaki, A. P., et al. (1994). Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues: effects of interleukin-1β, phorbol ester, and corticosteroids, J. Clin. Invest. 93, 1095–1101.PubMedGoogle Scholar
  17. Curzon, G. and Knott, P. J. (1973). Drugs influencing plasma and brain tryptophan, Br. J. Pharmacol. 48, 352P–353P.PubMedGoogle Scholar
  18. Curzon, G., Friedel, J. and Knott, P. J. (1973). The effect of fatty acids on the binding of tryptophan to plasma protein, Nature 242, 198–200.PubMedGoogle Scholar
  19. Davies, N. M. (1998). Clinical pharmacokinetics of oxaprozin, Clin. Pharmacokinet. 35, 425–436.PubMedGoogle Scholar
  20. Davis, R. H., Fisher, J. S. and McGowan, L. (1968). Local antiphlogistic activity of L-phenylalanine and L-tryptophane, J. Endocrinol. 41, 603–604.PubMedGoogle Scholar
  21. Dickens, B. F., Weglicki, W. B., Li, Y. S., et al. (1992). Magnesium deficiency in vitro enhances free radical-induced intracellular oxidation and cytotoxicity in endothelial cells, FEBS Lett. 311, 187–191.PubMedGoogle Scholar
  22. Dingle, J. T. (1983). Effect of NSAIDs on the production of catabolin by porcine synovium, Adv. Inflamm. Res. 10, 105–110.Google Scholar
  23. Dixon, J. S. and Page, M. C. (1991). Interactions between non-steroidal anti-inflammatory drugs and H2-receptor antagonists or prostaglandin analogues, Rheumatol. Int. 11, 13–18.PubMedGoogle Scholar
  24. Farndale, R. W., Buttle, D. J. and Barrett, A. J. (1986). Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue, Biochim. Biophys. Acta 883, 173–177.PubMedGoogle Scholar
  25. Fernstrom, J. D. and Wurtman, R. J. (1972). Brain serotonin content: physiological regulation by plasma neutral amino acids, Science 178, 414–416.PubMedGoogle Scholar
  26. Fitos, I. and Simonyi, M. (1986). Investigation on the binding of tryptophan enantiomers to human serum albumin, Acta Biochim. Biophys. 21, 237–245.Google Scholar
  27. Francesconi, R. P. and Mager, M. (1975). Salicylate, tryptophan, and tyrosine hypothermia, Am. J. Physiol. 228, 1431–1435.PubMedGoogle Scholar
  28. Fraser, A. D. and Howell, P. (1998). Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine, J. Anal. Toxicol. 22, 50–54.PubMedGoogle Scholar
  29. Freeland, G. R., Northington, R. S., Hedrich, D. A., et al. (1988). Hepatic safety of two analgesics used over the counter: ibuprofen and aspirin, Clin. Pharmacol. Ther. 43, 473–479.PubMedGoogle Scholar
  30. Friedman, P. A., Kappelman, A. H. and Kaufman, S. (1972). Partial purification and characterization of tryptophan hydroxylase from rabbit hindbrain, J. Biol. Chem. 247, 4165–4173.PubMedGoogle Scholar
  31. Gal, E. M. (1975). Hydroxylation of tryptophan and its control in brain, Pavlov J. Biol. Sci. 10, 145–160.PubMedGoogle Scholar
  32. Greenblatt, D. J., Matlis, R., Scavone, J. M., et al. (1985). Oxaprozin pharmacokinetics in the elderly, Br. J. Clin. Pharmacol. 19, 373–378.PubMedGoogle Scholar
  33. Griffin, J. P. and D'Arcy, P. F. (1997). A Manual of Adverse Drug Reactions. Elsevier, Amsterdam.Google Scholar
  34. Guerinot, F., Poitou, P. and Bohuon, C. (1974). Serotonin synthesis in the rat brain after acetylsalicylic acid administration, J. Neurochem. 22, 191–192.PubMedGoogle Scholar
  35. Heyliger, S. O., Goodman, C. B., Ngong, J. M., et al. (1998). The analgesic effects of tryptophan and its metabolites in the rat, Pharmacol. Res. 38, 243–250.PubMedGoogle Scholar
  36. Igari, T. and Shimamura, T. (1979). Serotonin metabolism and its enzymic activities in joint diseases, Clin. Orthoped. 139, 232–249.Google Scholar
  37. Igari, T., Obara, K., Ono, S., et al. (1979). Tryptophan metabolism in the joint diseases, Acta Vitaminol. Enzymol. 29, 194–197.Google Scholar
  38. Iwata, H., Okamoto, H. and Ko, S. (1975). Effects of various drugs on serum free and total tryptophan levels and brain tryptophan metabolismin rats, Jpn. J. Pharmacol. 25, 303–310.PubMedGoogle Scholar
  39. Janssen, F. W., Jusko, W. J., Chiang, S. T., et al. (1980). Metabolism and kinetics of oxaprozin in normal subjects, Clin. Pharmacol. Ther. 27, 352–362.PubMedGoogle Scholar
  40. Karim, A. (1996). Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications, J. Clin. Pharmacol. 36, 985–997.PubMedGoogle Scholar
  41. Karim, A., Noveck, R., McMahon, F. G., et al. (1997). Oxaprozin and piroxicam, nonsteroidal anti-inflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics, J. Clin. Pharmacol. 37, 267–278.PubMedGoogle Scholar
  42. Kawai, S., Nishida, S., Kato, M., et al. (1998). Comparison of cyclooxygenase-1 and-2 inhibitory activities of various non-steroidal anti-inflammatory drugs using human platelets and synovial cells. Eur. J. Pharmacol. 347, 87–94.PubMedGoogle Scholar
  43. Kelly, S. J. and Franklin, K. B. (1985). An increase in tryptophan in brain may be a general mechanism for the effect of stress on sensitivity to pain. Neuropharmacology 24, 1019–1025.PubMedGoogle Scholar
  44. Kema, I. P., de Vries, E. G. and Muskiet, F. A. (2000). Clinical chemistry of serotoninand metabolites, J. Chromatogr. B: Biomed. Sci. Appl. 747, 33–48.Google Scholar
  45. Kethu, S. R., Rukkannagari, S. and Lansford, C. L. (1999). Oxaprozin-induced symptomatic hepatotoxicity, Ann. Pharmacother. 33, 942–944.PubMedGoogle Scholar
  46. Khan, S. B. and Hubsher, J. A. (1983). Effects of oxaprozin alone or in combination with aspirin on hemostasis and plasma protein binding, J. Clin. Pharmacol. 23, 139–146.PubMedGoogle Scholar
  47. Knott, P. J. and Curzon, G. (1972). Free tryptophan in plasma and brain tryptophan metabolism, Nature 239, 452–453.PubMedGoogle Scholar
  48. Kurowski, M. and Thabe, H. (1989). The transsynovial distribution of oxaprozin, Agents Actions 27, 458–460.PubMedGoogle Scholar
  49. Lagrange, F., Penhourcq, F., Matoga, M., et al. (2000). Binding of ketoprofen enantiomers in various human albumin preparations, J. Pharm. Biomed. Anal. 23, 793–802.PubMedGoogle Scholar
  50. Lanza, F. L. (1993). Gastrointestinal toxicity of newer NSAIDs, Am. J. Gastroenterol. 88, 1318–1323.PubMedGoogle Scholar
  51. Lanza, F. L., Hubsher, J. A. and Walker, B. R. (1981). Gastroscopic evaluation of the effect of aspirin and oxaprozin on the gastric mucosa, J. Clin. Pharmacol. 21, 157–161.PubMedGoogle Scholar
  52. Lewis, A. J., Janssen, F. W., Bonney, S. L., et al. (1985). Oxaprozin, in: Anti-Inflammatory and Anti-Rheumatic Drugs, Vol. II: Newer Anti-In flammatory Drugs, Rainsford, K. D. (Ed.), pp. 189–208. CRC Press, Boca Raton, FL.Google Scholar
  53. Lucker, P. W., Venitz, J., Ahrens, S., et al. (1987). Gastric irritation of oxaprozin, a new nonsteroidal, anti-inflammatory drug, in comparison to acetylsalicyic acid and indomethacin: a gastric potential difference analysis, Methods Find. Exp. Clin. Pharmacol. 9, 469–475.PubMedGoogle Scholar
  54. Lussier, A., Lebel, E. and Tetreault, L. (1982). Gastrointestinal blood loss of oxaprozin and aspirin with placebo control, J. Clin. Pharmacol. 22, 173–178.PubMedGoogle Scholar
  55. Manoukian, A. V. and Carson, J. L. (1996). Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention, Drug Safety 15, 64–71.PubMedGoogle Scholar
  56. McArthur, J. N. (1979). The pharmacological consequences of the binding of anti-rheumatic drugs to plasma proteins in the treatment of rheumatoid arthritis, Agents Actions 9, 212–216.PubMedGoogle Scholar
  57. McArthur, J. N. and Dawkins, P. D. (1969). The effect of sodium salicylate on the binding of L-tryptophan to serum proteins, J. Pharm. Pharmacol. 21, 744–750.PubMedGoogle Scholar
  58. McArthur, J. N. and Smith, M. J. (1972). Action of salicylates, N. Engl. J. Med. 287, 361.Google Scholar
  59. McArthur, J. N., Smith, M. J. and Hamilton, E. B. (1971a). Protein-bound peptides in human serum, Br. Med. J. 4, 230.Google Scholar
  60. McArthur, J. N., Dawkins, P. D., Smith, M. J., et al. (1971b). Mode of action of antirheumatic drugs, Br. Med. J. 2, 677–679.PubMedGoogle Scholar
  61. McArthur, J. N., Smith, M. J. and Freeman, P. C. (1972). Anti-inflammatory substance in human serum, J. Pharm. Pharmacol. 24, 669–671.PubMedGoogle Scholar
  62. McMenamy, R. H. and Oncley, J. L. (1958). The specific binding of L-tryptophan to serum albumin, J. Biol. Chem. 233, 1436–1447.PubMedGoogle Scholar
  63. Miller, L. G. (1992). Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug, Clin. Pharm. 11, 591–603.PubMedGoogle Scholar
  64. Mitnick, P. D., Greenberg, A., Deoreo, P.B., et al. (1980). Effects of two nonsteroidal anti-infl ammatory drugs, indomethacin and oxaprozin, on the kidney, Clin. Pharmacol. Ther. 28, 680–689.PubMedGoogle Scholar
  65. Monaghan, J. M., Cook, K., Gara, D., et al. (1997). Determination of nitrite and nitrate in human serum, J. Chromatogr. A 770, 143–149.PubMedGoogle Scholar
  66. Oldendorf, W. H. (1971). Uptake of radiolabelled essential amino acids by brain following arterial injection, Proc. Soc. Exp. Biol. Med. 136, 385–386.PubMedGoogle Scholar
  67. Ochs, H. R., Greenblatt, D. J. and Knuchel, M. (1986). Oxaprozin pharmacokinetics in patients with congestive heart failure, Arzneimittelforschun g 36, 1837–1840.PubMedGoogle Scholar
  68. Pardridge, W. M. (1977). Regulation of amino acid availability in the brain, in: Nutrition and the Brain, R. J. Wurtman and J. J. Wurtman (Eds), pp. 141–204. Raven Press, New York, NY.Google Scholar
  69. Pulini, M. (1995). False-positive benzodiazepine urine test due to oxaprozin, J. Am. Med. Ass. 273, 1905–1906.Google Scholar
  70. Purdum III, P. P., Sheldon, S. L., Boyd, J. W., et al. (1994). Oxaprozin-induced fulminant hepatitis, Ann. Pharmacother. 28, 1159–1161.PubMedGoogle Scholar
  71. Rainsford, K. D. (1985). Preliminary investigations on the pharmacological control of catabolin-induced cartilage destruction in vitro, Agents Actions 16, 55–57.PubMedGoogle Scholar
  72. Rainsford, K. D. (1988). Comparative irritancy of oxaprozin on the gastrointestinal tract of rats and mice: relationship to drug uptake and effects in vivo on eicosanoid metabolism, Aliment Pharmacol. Ther. 2, 439–450.PubMedGoogle Scholar
  73. Rainsford, K. D., Brune, K. and Whitehouse, M. W. (Eds) (1981). Trace Elements in the Pathogenesis and Treatment of Inflammation. Birkhäuser Verlag, Basel, Boston, Stuttgart.Google Scholar
  74. Rainsford, K. D., Davies, A., Mundy, L., et al. (1989). Comparative effects of azapropazone on cellular events at inflamed sites. Influence on joint pathology in arthritic rats, leucocyte superoxide and eicosanoid production, platelet aggregation, synthesis of cartilage proteoglycans, synovial production and actions of interleukin-1 in cartilage resorption correlated with drug uptake into cartilage in vitro, J. Pharm. Pharmacol. 41, 322–330.Google Scholar
  75. Rainsford, K. D., Ying, C. and Smith, F. C. (1995). Effects of meloxicam compared with other NSAIDs, on cartilage proteoglycan metabolism, synovial prostaglandin E2 production and pro-duction of interleukins 1, 6 and 8, in human and porcine explants in organ culture, J. Pharm. Pharmacol. 48, 991–998.Google Scholar
  76. Rainsford, K. D., Ginsburg, I. and Gadd, S. J. (1997). A comparison between the effects of meloxicam and other NSAIDs on the production of oxyradicals by human polymorphonuclear leucocytes, Immunopharmacology 5, 9–19.Google Scholar
  77. Rainsford, K. D., Milanino, R., Sorenson, J. R. J., et al. (Eds) (1998), Copper and Zinc in Inflammatory and Degenerative Diseases. Kluwer Academic Publishers, Dordrecht, Boston, London.Google Scholar
  78. Rainsford, K. D., Skerry, T. M., Chindemi, P., et al. (1999). Effects of the NSAIDs, meloxicam and indomethacin, on cartilage proteoglycan synthesis and joint responses to calcium pyrophosphate crystals in dogs, Vet. Res. Commun. 23, 101–113.PubMedGoogle Scholar
  79. Rothstein, R. (1998). Safety profiles of leading nonsteroidal anti-inflammatory drugs, Am. J. Med. 105, 39S–43S.Google Scholar
  80. Ruelius, H. W., Kirkman, S. K., Young, E. M., et al. (1986). Reactions of oxaprozin-1-0-acyl glucuronide in solutions of human plasma and albumin, Adv. Exp. Med. Biol. 197, 431–441.PubMedGoogle Scholar
  81. Ruelius, H. W. (1987). Extrapolation from animals to man: predictions, pitfalls and perspectives, Xenobiotica 17, 255–265.PubMedGoogle Scholar
  82. Saklatvala, J., Pilsworth, L. M., Sarsfield, S. J., et al. (1984). Pig catabolin is a form of interleukin 1. Cartilage and bone resorb, fibroblasts make prostaglandin and collagenase, and thymocyte proliferation is augmented in response to one protein, Biochem. J. 224, 461–466.PubMedGoogle Scholar
  83. Sandyk, R. (1992). L-Tryptophan in neuropsychiatric disorders: a review, Int. J. Neurosci. 67, 127–144.PubMedGoogle Scholar
  84. Scavone, J. M., Greenblatt, D. J., Matlis, R., et al. (1986). Interaction of oxaprozin with aceta-minophen, cimetidine, and ranitidine, Eur. J. Clin. Pharmacol. 31, 371–374.PubMedGoogle Scholar
  85. Scavone, J. M., Ochs, H. R., Greenblatt, D. J., et al. (1988). Pharmacokinetics of oxaprozin in women receiving conjugated estrogen, Eur. J. Clin. Pharmacol. 35, 105–108.PubMedGoogle Scholar
  86. Shriver, D. A., Dove, P. A., White, C. B., et al. (1977). A profile of the gastrointestinal toxicity of aspirin, indomethacin, oxaprozin, phenylbutazone, and fentiazac in arthritic and Lewis normal rats, Toxicol. Appl. Pharmacol. 42, 75–83.PubMedGoogle Scholar
  87. Siegle, I., Klein, T., Backman, J. T., et al. (1998). Expression of cyclooxygenase-1 and cyclooxy-genase-2 in human synovial tissue. Differential evaluation of cyclooxygenase-2 in inflammatory joint diseases, Arth. Rheum. 41, 122–129.Google Scholar
  88. Simon, L. S., Zhao, S. Z., Arguelles, L. M., et al. (1998). Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis, Clin. Ther. 20, 1218–1235.PubMedGoogle Scholar
  89. Smith, H. G. and Lakatos, C. (1971). Effects of acetylsalicylic acid on serum protein binding and metabolismof tryptophan in man, J. Pharm. Pharmacol. 23, 180–189.PubMedGoogle Scholar
  90. Spano, P. F., Tagliamonte, A., Tagliamonte, P., et al. (1971). Stimulation of brain dopamine synthesis by gamma-hydroxybutyrate, J. Neurochem. 18, 1831–1836.PubMedGoogle Scholar
  91. Suwa, T., Urano, H., Kohno, Y., et al. (1987). Comparative studies on the gastrointestinal lesions caused by several nonsteroidal anti-inflammatory agents in rats, Agents Actions 21, 167–172.PubMedGoogle Scholar
  92. Tagliamonte, A., Tagliamonte, P., Perez-Cruet, J., et al. (1971a). Increase of brain tryptophan caused by drugs which stimulate serotonin synthesis, Nature New. Biol. 229, 125–126.PubMedGoogle Scholar
  93. Tagliamonte, A., Tagliamonte, P., Perez-Cruet, J., et al. (1971b). Effect of psychotropic drugs on tryptophan concentration in the rat brain, J. Pharmacol. Exp. Ther. 177, 475–480.PubMedGoogle Scholar
  94. Tagliamonte, A., Biggio, G., Vargiu, L., et al. (1973a). Free tryptophan in serum controls brain tryptophan level and serotonin synthesis. Life Sci. II, 12, 277–287.PubMedGoogle Scholar
  95. Tagliamonte, A., Biggio, G., Vargiu, L., et al. (1973b). Increase of brain tryptophan and stimulation of serotonin synthesis by salicylate. J. Neurochem. 20, 909–912.PubMedGoogle Scholar
  96. Todd, P. A. and Brogden, R. N. (1986). Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, Drugs 32, 291–312.PubMedGoogle Scholar
  97. Weaver, A., Rubin, B., Caldwell, J., et al., (1995). Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee, Clin. Ther. 17, 735–745.PubMedGoogle Scholar
  98. Weil-Fugazza, J., Godefroy, F. and Besson, J. M. (1979). Changes in brain and spinal tryptophan and 5-hydroxyindoleacetic acid levels following acute morphine administration in normal and arthritic rats, Brain Res. 175, 291–301.PubMedGoogle Scholar
  99. Weil-Fugazza, J., Godefroy, F., Coudert, D., et al. (1980). Total and free serum tryptophan levels and brain 5-hydroxytryptaminemetabolism in arthritic rats, Pain 9, 319–325.PubMedGoogle Scholar
  100. Wells, D. S., Janssen, F. W. and Ruelius, H. W. (1987). Interactions between oxaprozin glucuronide and human serum albumin, Xenobiotica 17, 1437–1449.PubMedGoogle Scholar
  101. Wong, C.-L., Wai, M.-K. and Roberts, M. B. (1980). The effect of aspirin and paracetamol on the increased naloxone potency induced by morphine pre-treatment, Eur. J. Pharmacol. 67, 241–246.PubMedGoogle Scholar

Copyright information

© VSP 2002 2002

Authors and Affiliations

  • K. D. Rainsford
  • H. Omar
  • A. Ashraf
  • A. T. Hewson
  • R. A. D. Bunning
  • R. Rishiraj
  • P. Shepherd
  • R. W. Seabrook

There are no affiliations available

Personalised recommendations